GLP-1

Orforglipron

Also known as LY3502970

Orforglipron is an experimental once-daily GLP-1 pill (not an injection) for weight and blood sugar, aiming to deliver GLP-1 benefits in a simple tablet with no food restrictions.

One-dose burn-down
Half-life
36 h
Range
24 h–2.8 days
Tmax
6.0 h
Bioavailability
79%
Steady state
~7d
Typical dose
3 mg

Investigational oral, non-peptide (small-molecule) GLP-1 receptor agonist taken once daily — without the food/water restrictions of oral semaglutide.

Mechanism of action

Small-molecule GLP-1 receptor agonist that is orally bioavailable without an absorption enhancer, enhancing glucose-dependent insulin secretion and appetite suppression.

Investigational — not FDA approved. PK from phase 1 studies; once-daily oral dosing.

Track Orforglipron for free

Log your doses and PeptideBuddy models Orforglipron's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.

Start tracking free
Phase 1 PK (PubMed)

Related GLP-1